<DOC>
	<DOC>NCT02167451</DOC>
	<brief_summary>The purpose is to determine if the addition of Maraviroc to a standard transplant regimen will reduce the incidence of graft versus host disease in children and young adults after a stem cell transplant.</brief_summary>
	<brief_title>Maraviroc as GVHD Prophylaxis in Transplant Recipients</brief_title>
	<detailed_description>In the first stage, drug levels will be obtained to establish appropriate dosing. In the second stage of the study the investigators will study the effects of using Maraviroc in these patients.</detailed_description>
	<mesh_term>Graft vs Host Disease</mesh_term>
	<mesh_term>Maraviroc</mesh_term>
	<criteria>Ages 5 years and &lt;/= 40 years All diagnoses Marrow or cord blood All conditioning regimens Patient must be planned to receive a calcineurin inhibitor (cyclosporine or tacrolimus) together with steroid, methotrexate or mycophenolate mofetil as GVHD prophylaxis. Documented anaphylaxis to Maraviroc Ex vivo Tcell (type of white blood cell) depleted grafts Abnormal Alanine Aminotransferase (ALT) (&gt;/=10X ULN) on day 3. (Assessed at study enrollment and confirmed again prior to the first dose of maraviroc.)</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>stem cell transplant</keyword>
	<keyword>GVHD prevention</keyword>
</DOC>